Optimizing the diagnosis of Parkinsonian syndromes with 123I-ioflupane brain SPECT

Kevin P. Banks, Justin G. Peacock, Michael N. Clemenshaw, Phillip H. Kuo

Research output: Contribution to journalReview article

Abstract

OBJECTIVE. The purpose of this article is to provide a review of 123I-ioflupane SPECT in the evaluation of suspected parkinsonian syndromes (PSs). This collection of diseases presents frequent diagnostic challenges, even by movement disorder and dementia specialists. CONCLUSION. The 123I-ioflupane scan serves as an imaging biomarker of the status of presynaptic dopamine transporters (DATs) in the striatum. As a result of neuronal death, DATs are greatly reduced in patients with PS neurodegenerative disorders, whereas clinical mimics generally do not show striatal DAT loss. This provides a tremendous opportunity for 123I-ioflupane to aid in the accurate and timely diagnosis of these patients and optimize their management.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalAmerican Journal of Roentgenology
Volume213
Issue number2
DOIs
StatePublished - Jan 1 2019

Keywords

  • Dementia
  • Dopamine
  • Ioflupane
  • Parkinsonian syndromes
  • Striatum

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Optimizing the diagnosis of Parkinsonian syndromes with <sup>123</sup>I-ioflupane brain SPECT'. Together they form a unique fingerprint.

  • Cite this